Placeholder Banner

BIO Welcomes John Delacourt as Deputy General Counsel

March 15, 2023
Media Contact
Karen Batra
202.449.6382

Mr. Delacourt is a senior litigator and regulatory counselor with more than a decade of experience advising biotech companies

WASHINGTON – (March 15, 2023) – The Biotechnology Innovation Organization (BIO) welcomes John Delacourt as Deputy General Counsel – VP Health, Regulatory, and Commercial Operations. John will work with BIO’s staff to lead legal support for commercial operations and with its membership to ensure patient access to life-saving medicines, bring down barriers to innovation, and promote policies conducive to advances in agriculture and environmental science.

 John comes to BIO from another biotech trade group – the Plasma Protein Therapeutics Association (PPTA) – where he served as Chief Legal Officer & Head of Global Policy. While at PPTA, John led the association’s litigation defense and regulatory compliance efforts in both the United States and Europe. He also served as legal advisor to PPTA’s principal governing bodies, including on such issues as drug shortage preparedness, discriminatory labeling practices, and secure handling of biometric data.

Prior to joining PPTA, John practiced at major law firms in Washington, D.C. and New York. He also served in senior roles at the Federal Trade Commission, including as Chief Antitrust Counsel of the FTC’s Office of Policy Planning.

“John’s healthcare and compliance experience make him a welcome addition to our growing legal team,” said Chief Legal Officer Peter McHugh. “As BIO continues to address the legal challenges presented by the Inflation Reduction Act, advocate for efficient market access for innovative products, and support a favorable environment for biotech investment, we are excited to have John on our side.”

John is a graduate of Georgetown University and Harvard Law School.

Discover More
BIO President & CEO John F. Crowley released the following statement:“A healthy and prosperous society is vitally important to the American people and to the world. The public health, economic security and our national security are best served…
“The Biotechnology Innovation Organization (BIO) applauds today's announcement from the USDA's Animal and Plant Health Inspection Service (APHIS) expanding the scope of biotechnology exemptions for modified plants under 7 CFR part 340. This…
BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities."Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient…